Skip to content

Cognitive Leisure and Preclinical Alzheimer's Disease: Exploring Neural Mechanisms

The Impact of Cognitive Leisure Activity Levels on Cognitive Function in the Preclinical Stage of Alzheimer's Disease and the Study of Its Neural Circuitry Regulation Mechanisms

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06215274
Enrollment
156
Registered
2024-01-22
Start date
2024-04-27
Completion date
2026-12-31
Last updated
2024-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction

Keywords

Alzheimer's Disease, Cognitive Leisure activity, MRI

Brief summary

The goal of this clinical trial is aims to: 1. Translate and culturally adapt the Cognitive Leisure Activity Scale (CLAS) into Chinese and Conduct reliability and validity tests for the Chinese version of CLAS. 2. Investigate the correlation between cognitive leisure activity levels and cognitive function in the preclinical stage of Alzheimer's Disease (AD). 3. Clarify the regulatory mechanisms of cognitive leisure activity levels on the neural circuits of patients in the preclinical stage of AD.

Detailed description

Alzheimer's disease (AD), also known as senile dementia, is the most common neurodegenerative disorder characterized by progressive decline in cognitive function and behavioral impairment. It is estimated that there are approximately 9.83 million AD patients in China, with an average annual treatment cost of about $19,144 per person, accounting for 1.47% of the national gross domestic product, surpassing the global average. This not only severely affects the quality of life for elderly patients but also imposes a heavy economic and caregiving burden on families and society. Due to the limitations of AD treatment and the irreversibility of its progression, early detection and intervention have become the focus of AD prevention and control efforts. Increasingly, scholars propose shifting the diagnosis and intervention of AD to the preclinical stage, particularly the mild cognitive impairment (MCI) phase and even earlier stages characterized by subjective cognitive decline (SCD). Cognitive leisure activity, as one of the potentially modifiable factors in the preclinical stage of AD, understanding its impact on cognitive function and the neural circuitry regulation mechanisms in this stage is of significant importance. This knowledge can contribute to the development of early targeted intervention measures, preventing or delaying the onset and progression of AD, and promoting healthy aging.

Interventions

OTHERRelationship of the cognitive leisure activity levels, cognitive function, and MRI characteristics.

The cognitive leisure activity levels, cognitive function, and MRI characteristics in people in the preclinical stage of Alzheimer's Disease (AD).

Sponsors

Yuanjiao Yan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of Mild Cognitive Impairment (MCI) and Subjective Cognitive Decline (SCD) * Age ≥ 60 years * Capable of normal communication in Mandarin,possesses a certain level of comprehension and judgment.

Exclusion criteria

* Individuals with severe hearing or language impairments, or with severe physical illnesses that are unable to cooperate with the survey * Individuals with pacemakers, metallic implants, cochlear implants, claustrophobia, and other contraindications for MRI examination.

Design outcomes

Primary

MeasureTime frameDescription
Cognitive leisure activity levelsBaselineThe Chinese version of Cognitive & leisure activity scale will be used. Utilizing the Likert 5-point scale with 16 items, total score ranges from 0 to 80 points,higher scores signify increased cognitive leisure activity levels. An abnormal level is determined if the score is below 25 points.

Secondary

MeasureTime frameDescription
Visuospatial skillsBaselineThe Chinese version of Rey-Osterrieth Complex Figure Test will be used. A higher score indicates better visual-spatial structural abilities.
Naming difficultyBaselineThe Chinese version of Boston Naming Test will be used. The total scores range from 0 to 30, a higher score indicates better language functioning.
MemoryBaselineThe Chinese version of Auditory Verbal Learning Test will be used. This includes immediate memory, short-term memory, long-term memory, and recognition memory. A higher score indicates better memory performance.
Verbal fluencyBaselineThe Chinese version of Verbal Fluency Test will be used. A higher score indicates better verbal language performance.
Executive functionBaselineThe Chinese version of Shape Trail Test will be used. The shorter the usage time indicates better executive functioning.
Regional HomogeneityBaselineThe rest-state functional MRI of Regional Homogeneity analysis will be performed to investigate the variations in MRI features across different cognitive leisure activities and levels of cognitive functioning.
Functional ConnectivityBaselineThe rest-state functional MRI of Functional Connectivity analysis will be performed to investigate the variations in MRI features across different cognitive leisure activities and levels of cognitive functioning.
General cognitive functionBaselineThe Chinese version of Montreal Cognitive Assessment will be used.The scale has a total score of 30 points, encompassing eight assessment sections: visual-spatial and executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. It involves multiple cognitive domains. A higher score indicates better cognitive functioning.
Amplitude of Low-Frequency FluctuationsBaselineThe rest-state functional MRI of Amplitude of Low-Frequency Fluctuations analysis will be performed to investigate the variations in MRI features across different cognitive leisure activities and levels of cognitive functioning.

Countries

China

Contacts

Primary ContactFayang Lian, MD
fjslkyk@163.com0591-87557768

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026